Kazia Therapeutics Appoints Robert Apple to Board, Bolstering Leadership

TL;DR

**Kazia Therapeutics just added a seasoned pharma CEO to its board, signaling a leadership upgrade.**

AI Summary

Kazia Therapeutics Limited, a pharmaceutical company, announced on January 18, 2024, the appointment of Robert Apple to its Board of Directors, effective January 15, 2024. Mr. Apple brings over 25 years of senior leadership experience in the pharma industry, including 16 years at Antares Pharma, Inc. where he served as CEO and CFO. This board renewal aims to strengthen the company's leadership, which could be a positive signal for investors looking for experienced guidance in the company's strategic direction.

Why It Matters

Adding an experienced pharma executive like Robert Apple to the board can bring valuable strategic insights and financial acumen, potentially improving company performance and investor confidence.

Risk Assessment

Risk Level: low — The appointment of an experienced director is generally a positive development and does not introduce significant new risks.

Analyst Insight

A smart investor would view this as a positive step towards strengthening leadership and consider it a minor bullish signal, potentially warranting further research into Kazia's pipeline and overall strategy.

Key Players & Entities

• Kazia Therapeutics Limited (company) — registrant
• Robert Apple (person) — newly appointed Director and former CEO/CFO of Antares Pharma
• Antares Pharma, Inc. (company) — Mr. Apple's previous employer for 16 years
• InKine Pharmaceutical Company (company) — Mr. Apple's previous employer
• PaxMedica Inc (company) — company where Mr. Apple served on the Board
• January 15, 2024 (date) — effective date of Robert Apple's appointment
• January 18, 2024 (date) — date of the press release announcing the appointment

Forward-Looking Statements

• The appointment of Robert Apple will lead to enhanced strategic decision-making and potentially improved financial performance for Kazia Therapeutics. (Kazia Therapeutics Limited) — medium confidence, target: 2025-01-18

FAQ

Filing Documents

• d620838d6k.htm (6-K) — 12KB
• d620838dex991.htm (EX-99.1) — 10KB
• g620838g48h22.jpg (GRAPHIC) — 10KB
• g620838g97f50.jpg (GRAPHIC) — 6KB
• 0001193125-24-010234.txt ( ) — 44KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT Appointment of Director Appointment of Director; Appointment of Chairman On January 15, 2024, the Board of Directors (the Board) of Kazia Therapeutics Limited (the Company) appointed Robert Apple to the Board. On January 18, 2024, the Company issued a Press Release titled, Kazia Continues Board Renewal with Two New Appointments. A copy of this release is furnished as Exhibit 99.1 and is incorporated herein by reference. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to the Company, including 16 years with Antares Pharma, Inc. (Antares), where he served as Senior Vice President, Chief Financial Officer, Corporate Secretary, President, and Chief Executive Officer. Prior to Antares, Mr. Apple was Chief Operating and Financial Officer at InKine Pharmaceutical Company. Mr. Apple served on the Board of Directors at Antares from 2016 until May 2022. Mr. Apple has also served on the Boards of, InKine Pharmaceutical, PaxMedica Inc, and Kerathin Inc. He also held prior roles at Genaera Corporation, Liberty Technologies, and Arthur Andersen & Company. Mr. Apple has a Bachelor of Accounting from Temple University, Philadelphia. The Board also appointed Bryce Carmine to the role of Chairman of the Board, effective as of January 10, 2024. Mr. Carmine joined the Board as a Director in 2015, following a long and distinguished career at Eli Lilly & Co. (Lilly) where he served as Executive Vice President, and also as President for Lilly Bio-Medicines. Prior to this, he led the Global Pharmaceutical Sales and Marketing division and was a member of the companys Lillys Executive Committee. Mr. Carmine previously held a series of product development portfolio leadership roles at Lilly culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Lilly. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Dr. John Friend in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-259224 and 333-276091). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated January 18, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 18 January 2024

View Full Filing

View this 6-K filing on SEC EDGAR